Please assess the completion status of the following clinical trial:

Trial Title: Study on Rosuvastatin+Ezetimibe and Rosuvastatin for LDL-C Goal in Patients With Recent Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with recent ischemic stroke who meet both 1) and 2) criteria below. 1) Patients with acute ischemic stroke confirmed by DWI(diffusion-weighted imaging)~   This is satisfied by meeting at least one of the following two criteria:~  1. Patients who sustained stroke symptoms for more than 24 hours and had acute ischemic lesions on DWI.~  2. Patients with acute ischemic lesions in DWI who had improved symptoms within 24 hours.~      2) Patients with ischemic stroke within 90 days.~2. Statin therapy indicated according to the recommendations of the 2014 American Heart Association/American Stroke Association guidelines.~   This is accomplished by meeting at least one of the following three criteria:~  1. Patients with ischemic stroke due to arteriosclerosis and LDL-C ≥ 100 mg / dL. (Class I; Level of Evidence B)~  2. Patients with ischemic stroke due to arteriosclerosis and LDL-C \<100 mg / dL. (Class I; Level of Evidence C)~  3. Patients who require statin therapy due to other associated atherosclerotic cardiovascular disease. (Class I; Level of Evidence A).~3. Patients without statin dose within 28 days before ischemic stroke.~4. Patients who measured baseline LDL-C levels after an ischemic stroke. This is satisfied by meeting at least one of the following two criteria:~   1. Patients who had a baseline LDL-C level before the onset of a recent ischemic stroke and started statin therapy.~  2. Patients hospitalized with acute ischemic stroke who had baseline LDL-C levels after initiation of statin therapy should meet both of the following conditions:~      1. Patients with LDL-C levels measured within 3 days after initiation of statin therapy~     2. Patients in whom randomization and administration of the study drug can be administered within 7 days after baseline LDL-C measurement.~5. Adults over 19 years.~6. Those who voluntarily agreed in writing to the trial.~Exclusion Criteria:~1. Planned vascular intervention before the end of trial~2. Significant hepatic dysfunction (Aspartate Aminotransferase or Alanine Aminotransferase \>120 IU/L)~3. Allergy or contraindication to rosuvastatin or ezetimibe~4. Alcohol or drug addiction~5. Pregnancy or breast-feeding~6. Severe anemia: Hb level \<10 g/dL for men and \<9 g/dL for women~7. Bleeding diathesis: platelet count \<100,000/μl or prothrombin time International Normalized Ratio \> 1·7~8. Inability or unwillingness to comply with study-related procedures~9. Employees of the investigator or study center, with direct involvement in the current study~10. Women unwilling to continue contraception during the study period~11. Participation in other clinical trials within three-month~12. Malignancy or other serious medical conditions with a life expectancy \<6 months~13. Treatment with protease inhibitors or cyclosporine~14. Patients with severe renal impairment (creatinine clearance \<30 mL / min)~15. Other reasons for ineligibility judged by investigators

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rosuvastatin/Ezetimibe 10/10mg (Type: EXPERIMENTAL): The experimental group is orally administered with rosuvastatin 10 mg plus ezetimibe 10 mg combination once daily for 90 days.
- Rosuvastatin 20mg (Type: ACTIVE_COMPARATOR): The comparator group is orally administered with rosuvastatin 20 mg single agent once daily for 90 days

Based on this trial design, predict the completion outcome and termination type (if applicable).